Another death blights Astellas' $3B Audentes buy as FDA slaps clinical hold on the test UPDATE: Pfizer and Trillium: How a $25M investment led to a $2.3B buyout After 3 big exits, Lightstone snags largest fund yet with $375M geared toward next biotechs, medtechs Sponsored: Four Steps to Smarter, More Dynamic Deployment Independent report confirms sexual harassment claims against anti-aging researcher de Grey Stem cell biotech ViaCyte staffs up CSO role to drive diabetes treatments Kapeller's Rome bags $77M to strike gold in the backwaters of the genome RedHill BioPharma follows familiar biotech path after COVID-19 drug fails in severe patients Vanqua Bio snags $85M series B to vanquish Parkinson's, Gaucher, ALS and Alzheimer's iRhythm gets back on beat, tapping former Dexcom exec as CEO Attacking Alzheimer's by blocking 'frustrated' amyloid proteins before they form plaques From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year Majority of hospitals stumbled on public health reporting before the strain of a global pandemic Featured Story | By Ben Adams Astellas has seen a fourth death in its gene therapy trial of an experimental drug gained through the pharma’s $3 billion buyout of biotech Audentes. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Pfizer was in a hurry to seal its takeover of cancer startup Trillium Therapeutics, a relationship that was first sparked after the Big Pharma spied some early clinical data at the American Society of Clinical Oncology in June 2020. read more By Kyle LaHucik After seeing Ra Pharma, Disarm and Tizona to exits last year, Lightstone Ventures is back with $375 million to plant a seed in early-stage biotech and medtech startups. read more Sponsored by: IQVIA Are you using data and analytics to design smarter campaigns and more effective sales rep deployment? read more By Annalee Armstrong An independent review has confirmed allegations of sexual harassment against the SENS Research Foundation’s former chief science officer Aubrey de Grey, who was fired last month for attempting to pressure one of the complainants. read more By Emmy Lucas Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia. Timothy Kieffer will join the clinical-stage regenerative medicine biotech as CSO. read more By Nick Paul Taylor Rosana Kapeller’s Rome Therapeutics has pulled in $77 million to target vast, untapped parts of the genome. With VCs ranging from Section 32 to Sanofi Ventures now behind it, Rome is working to hustle autoimmune and cancer drugs toward the clinic. read more By Ben Adams RedHill Biopharma has rolled snake eyes in a late-stage trial for its experimental COVID-19 treatment, the SK2 inhibitor opaganib, which has failed to help severely ill patients. read more By Kyle LaHucik Vanqua Bio secured an $85 million series B to take its lead program into the clinic within two years for Gaucher disease and a specific form of Parkinson's disease. Further down the pipeline, Vanqua aims to treat Alzheimer's, ALS and potentially other neurodegenerative diseases through the lens of the innate immune system. read more By Andrea Park About four months after the abrupt exit of CEO Mike Coyle, a new leader is taking the helm at cardiac monitor maker iRhythm Technologies. read more By Arlene Weintraub Researchers at the University of Houston and Rice University discovered that amyloid beta peptides encounter several obstacles in the quest to attach to protein aggregates in the brain known as fibrils. Drugs that exploit the points at which the peptides are held back could prove promising in Alzheimer's and other brain diseases, they suggested. read more By Noah Higgins-Dunn Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Cumulatively, the meds are worth roughly $7.1 billion in sales by 2026. read more By Dave Muoio A recent data brief from the ONC suggests that most hospitals had issues electronically exchanging information with public health agencies well before the strain of a global pandemic. read more | | The life-changing potential of cell & gene therapy demands lab services that are just as transformative. LabConnect® leads the evolution of lab services with customized solutions that simplify clinical trial complexity. Let us help with your next study so you can focus on the research. Learn more. |
Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Medical Affairs Strategic Summit (MASS) September 13-15, 2021 | New Brunswick, NJ Let A Digital Sherpa Uncomplicate The Path for Patients Wednesday, September 15 | 1 PM ET Sea-dumped chemical weapons: environmental risk, occupational hazard September 22, 2021 1pm EST Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA The MedTech Conference 2021 September 27 - 30, 2021 Introduction to Structure Elucidation in Drug Development Sep 29, 2021 1 pm EST Pharma PR & Communications Summit October 4-5, 2021 | Jersey City, NJ Virtual U.S. Healthcare Compliance Certificate Program October 11 – 14, 2021 Fierce Biotech Cell & Gene Therapy October 19, 2021 | Virtual Event Fierce Health Payer Summit October 26, 2021 | Virtual Event Announcing the 9th International mRNA Health Conference November 09-10, 2021 | Mercure MOA Berlin & Online Diversity, Equity & Inclusion Week November 9–11, 2021 | Virtual Event Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Fierce Biotech Forum 2022 | Virtual Event | 